June 12, 2025 – birdflustocks.com

birdflustocks.com

Home
Facts
Idea
Stocks
Brokers

June 12, 2025

birdflustocks.com » 2025 June 12

June 12, 2025

CureVac/BioNTech: BioNTech will acquire CureVac in an all share deal with a 55% premium

By admin | 12 Jun, 25 |

Search

Recent Posts

Merck/Cidara Therapeutics: Acquisition of Cidara Therapeutics for 221.5 USD/share confirmedNovember 14, 2025
CureVac/BioNTech: BioNTech will acquire CureVac in an all share deal with a 55% premiumJune 12, 2025
Moderna: BARDA funding for phase 3 H5N1 vaccine trial terminatedMay 28, 2025
Moderna: Positive phase 1/2 H5N1 vaccine interim dataMay 28, 2025
CureVac/BioNTech: European Patent Office maintains amended CureVac patent EP 3 708 668 B1 challenged by BioNTechMarch 27, 2025
GSK: Canada orders 500.000 H5N1 vaccine dosesFebruary 19, 2025
Moderna: 590 million USD BARDA funding for bird flu mRNA vaccine developmentJanuary 17, 2025
Arcturus Therapeutics: Phase 1 H5N1 mRNA vaccine trial initiatedJanuary 10, 2025
CSL: United Kingdom government orders 5 million H5 vaccine dosesDecember 3, 2024
Cidara Therapeutics: 105 million USD private placement funding announcedNovember 21, 2024
Arcturus Therapeutics: FDA clearance for Arcturus Therapeutics phase 1 bird flu vaccine trialNovember 11, 2024
CSL/GSK/Sanofi: 193 million USD BARDA contracts for bird flu vaccinesOctober 4, 2024
Cidara Therapeutics: Workforce to be reduced by 30% to focus on CD388September 12, 2024
Cidara Therapeutics: Cidara Therapeutics presents at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9, 2024
Vir Biotechnology: Development of antibody VIR-2981 against influenza discontinuedAugust 1, 2024
CureVac/GSK: GSK acquires full rights to influenza vaccines from CureVacJuly 3, 2024
Moderna: BARDA funding for phase 3 trial of H5N1 mRNA vaccineJuly 2, 2024
Moderna/BioNTech/Pfizer/GSK/Sanofi: Moderna defends mRNA patent, appeal likelyMay 17, 2024
GSK/BioNTech/Pfizer: Additional mRNA litigationApril 26, 2024
Cidara Therapeutics: Cidara Therapeutics reacquires global rights to CD388 from Johnson & Johnson, announces financing of 240 million USD, will proceed with CD388 phase 2b study in autumn 2024April 24, 2024
Cidara Therapeutics: Divestiture of rezafungin to focus on Cloudbreak DFC pipeline, including CD388April 24, 2024
CureVac/GSK: Start of combined phase 1/2 study for avian influenza (H5N1) mRNA vaccineApril 24, 2024
CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 studyApril 4, 2024
SAB Biotherapeutics: Partnership with Naval Medical Research Center for SAB-176 studyMarch 25, 2024
Vir Biotechnology/GSK: Antibody cooperation endedFebruary 23, 2024
BioNTech/CureVac: German court voids CureVac patent after BioNTech challenge, stock drops 41%December 19, 2023
BioNTech/Moderna: EPO revokes Moderna patent in vaccine dispute with BioNTechNovember 21, 2023
GSK: GSK sells Haleon shares to sharpen its focus on vaccines and infectious diseasesOctober 7, 2023
BioNTech/Pfizer: Pfizer and BioNTech resolve mRNA patent lawsuit filed by PromosomeOctober 7, 2023
Moderna: mRNA-1010 Seasonal Influenza Vaccine phase 3 study successfully completedSeptember 13, 2023
CureVac/GSK: mRNA seasonal influenza vaccine development advances to phase 2 studySeptember 12, 2023
Cidara Therapeutics/Johnson & Johnson: CD388 cooperation will continue, stock +26%September 6, 2023
Vir Biotechnology: VIR-2981 appears on pipeline page, indicating GSK collaborationAugust 6, 2023
Moderna: mRNA-1010 phase 3 study data coming soon?July 23, 2023
Cidara Therapeutics/Johnson & Johnson: CD388 study continuation uncertainJuly 21, 2023
Vir Biotechnology: VIR-2482 phase 2 study failed, stock drops 44%July 20, 2023
BioCryst Pharmaceuticals: BofA upgraded BioCryst (BCRX) to Buy from Neutral with a $10 price targetJuly 13, 2023
Cidara Therapeutics: CD388 phase 2 study data coming soon?July 13, 2023
Vir Biotechnology: VIR-2482 phase 2 study data coming soon?July 13, 2023
Sanofi: mRNA seasonal influenza vaccine development to be restarted with advanced technologyJune 30, 2023
SAB Biotherapeutics: SAB-176 Phase 2a study completed, FDA has granted Fast Track designationApril 13, 2023
Johnson & Johnson: Janssen to Discontinue Pimodivir Influenza Development ProgramSeptember 3, 2020

Recent Comments

No comments to show.

Archives

November 2025
June 2025
May 2025
March 2025
February 2025
January 2025
December 2024
November 2024
October 2024
September 2024
August 2024
July 2024
May 2024
April 2024
March 2024
February 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
April 2023
September 2020

Categories

bird flu stocks

Advertisement

Advertisement

Contact

Edulife Limited

71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom

info@birdflustocks.com

Menu

Data privacy statement

Financial disclaimer

Medical disclaimer

About

This website is about the risk of an influenza pandemic from a financial perspective. This does not constitute medical advise or financial advise.

© 2023 Edulife Limited